AzTrials
AzTrials

Dementia in Nursing HomeNCT06978972

Cognitive Stimulation Therapy for Residents With Dementia in Nursing Homes

A study testing Cognitive Stimulation Therapy in people with Dementia in Nursing Home, run by Northern Kentucky University at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The goal of this experimental study was to evaluate whether cognitive stimulation therapy (CST) improved cognitive functioning and engagement levels in individuals with mild-to-moderate dementia residing in long-term care facilities. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Dementia in Nursing Home
What is being tested?
Cognitive Stimulation Therapy
Could I receive a placebo?
No, everyone receives an active treatment
How many people
10 participants
Where
1 siteUnited States
Study dates
14 May 2025to 20 Aug 2025
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Provide informed consent
  • Adults aged 18 years or older who reside in a long-term care facility
  • Adequate English proficiency, vision, hearing, and speech to participate in groups
  • English proficiency
  • participation in recreational or social activities for at least 45 minutes per week
  • diagnosis of mild-to-moderate dementia based on Diagnostic and Statistical Manual of Mental Disorders (5th ed.; DSM-5) criteria, confirmed by medical records, or a mid-range score (18-55) on the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog)

Who cannot join

  • Prior CST treatment
  • non-English speaking
  • Communication barriers (aphasia)
  • Diagnosis of severe dementia
  • History of a learning disability or traumatic brain injury
  • Participation in a concurrent clinical trial
  • Receiving hospice care
  • ADAS-Cog score in the no-impairment range (0-17) or high range (56-70).

Trial locations and contacts

1 site in 1 country.

United States1 site
  • Ridgewood Health Campus

    Lawrenceburg, Indiana, 47025

Other trials in United States

About this study

Official title: Cognitive Stimulation Therapy for Residents With Dementia in Long-Term Facilities: A Quasi-Experimental Study

The goal of this experimental study was to evaluate whether cognitive stimulation therapy (CST) improved cognitive functioning and engagement levels in individuals with mild-to-moderate dementia residing in long-term care facilities. The study aimed to: 1) investigate the preliminary effect of CST on cognition and engagement in individuals with mild-to-moderate dementia, and 2) assess the feasibility of implementing CST in LTC facilities in the Cincinnati metropolitan area.

The main question the study answered was: Does CST improve cognitive functioning and increase engagement levels in individuals with mild-to-moderate dementia living in long-term care facilities?

Read more

Researchers conducted CST (structured, themed, grouped sessions with activites related to their childhood, sounds, word and number games, current affairs, being creative, word association, physical games, quizzes, and orientation) sessions to see if there was a significant increase in cognition and engagement after the 7 weeks of activites.

Participants received CST for 45 to 60 minutes twice weekly for 7 weeks, led by two doctor of occupational therapy students under the supervision of a licensed occupational therapist in the state of Indiana. Participants completed assessments before and after the 7-weeks to measure changes in cognitive function and engagement, along with participating in a screening assessment before the start of the study.

Read the detailed description

This study was a quasi-experimental one group pretest-posttest designed to evaluate the significance of a 7-week CST program among residents of a long-term care facility with mild to moderate dementia. The primary aim was to investigate the preliminary effect of CST on cognition and engagement in individuals with mild-to-moderate dementia.

The study was conducted at Ridgewood Health Campus and aimed to enroll approximately 10 participants over an estimated period of 1 to 2 months. Recruitment was completed with one research team member meeting site staff, where she presented the study and prepared them to identify eligible individuals based on the inclusion criteria. Site staff then provided a list of potential participants and gave access to relevant medical records, which the research team reviewed before reaching out to potential participants and/or their legal representatives via email, phone, or in person.

Interested participants and their Powers of Attorney (POAs) received an informational handout explaining study expectations. If the POA expressed interest in participation, an electronic version of the informed consent form was provided and reviewed. Research team members were available to address questions via phone, email, Zoom, or in person. The signed consent forms were returned electronically or physically, and a copy was retained by the participant and/or their POA.

As 10 participants enrolled, they first completed a one-week screening period, followed by one week of pre-testing. The CST intervention was administered twice weekly for 45 minutes over 7 weeks, followed by a one-week post-intervention assessment period.

To ensure fidelity of the CST intervention, the Principal Investigator (PI) and Co-Investigators (Co-PIs) completed formal training through the North American Cognitive Stimulation Therapy Training Institute through Saint Louis University, School of Medicine. The CST practice manual was also followed strictly. The research team then collaborated closely with on-site staff to address concerns related to participant safety, treatment environment, or study procedures. In the event of an adverse event, the research team planned to follow all HIPAA and facility protocols and planned to report the incident to the PI.

Given the vulnerability of the participant population, the research team prioritized ethical considerations. All study materials, including the participant handout and consent forms, were written in plain language and at an appropriate reading level. Power of Attorneys were given adequate time and support to make informed decisions. Additionally, on-site staff (nursing staff and aides) who were familiar with the participants were present during sessions to help meet their individual needs and advocate on their behalf. Additionally, because occupational therapy students co-facilitated the CST sessions, a licensed occupational therapist was present for all sessions to ensure participant safety and to ensure proper implementation of the intervention.

Participation was entirely voluntary, and participants could withdraw from the study at any time without penalty or loss of benefits. Participants were able to decline individual sessions or activities without consequence. During evaluations, participants were able to skip any question they did not wish to answer. Data from assessments were included in the analysis only if at least 75% of items were completed per participant. If a participant attended greater than or equal to 50% of the scheduled sessions (7 out of 14 sessions), their data was retained for analysis. Data from participants who attended fewer than 7 sessions were planned to be included from analysis, and this was addressed in the final report.

CST has not been associated with harmful side effects in previous studies, suggesting minimal risk to participants. Nonetheless, the possibility of emotional discomfort or other adverse events remained. Psychological effects were monitored, and any incident was planned to be addressed promptly following institutional and facility procedures. A potential risk includes unintentional disclosure of identifiable information, although safeguards have been implemented to mitigate this.

Data collection was managed using an encrypted password-protected flash drive with encryption and a password-protected file folder. Participant names were linked to unique ID codes necessary for tracking consent and study progress. Only coded identifiers were used in outcome data collection. Names were recorded solely on consent forms and a separate secure document linking names to ID codes, which will be stored for six years in accordance with data retention policies. After this period, all physical and electronic data will be securely destroyed.

Access to data was and will continue to be restricted to the PI and four Collaborative Institutional Training Initiative program (CITI) certified research members. Electronic documents were stored on two secure, encrypted, and password-protected flash drives. All team members' laptops are password-protected and use two-factor authentication. Devices have been and will continue to be stored securely when not in use, and team members adhere to strict data security practices when in public settings. Physical copies of data are stored in a password-protected file folder and stored with the faculty advisor.

All study procedures comply with Northern Kentucky University's institutional ethical guidelines. All protocol changes were submitted to the Institutional Review Board (IRB) before the start of the intervention and were approved. Data management followed validated protocols with comprehensive quality control measures to ensure the integrity and confidentiality of all collected data.

Being tested
Cognitive Stimulation Therapy
Keywords
Skilled nursing facilities, occupational engagement, cognitive functioning, Cognitive stimulation therapy, dementia, Group intervention, long-term care, geriatrics
Medical subject headings
Dementia

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Cognitive Stimulation TherapyOther

    CST is an evidence-based, cognitively stimulating therapeutic group intervention for individuals with mild-to-moderate dementia. Individuals participate in CST 2 times per week for 7 weeks. The CST sessions are administered by a variety of professionals who become certified through the St. Louis School of Medicine. The general structure of each session will follow the CST Manual called "Making a Difference 1". Each session will be based on a theme and will include an introduction, theme song, current affairs activity, the main activity (physical games, sounds, food, being creative, word and number games, team quizzes, orientation, current affairs, ect.), suggested activities for home, and closure. These sessions are highly structured and will follow the introduction, theme song, current affairs activity, the main activity, suggested activities for home, and closure organization strictly. The participants will spend 45 minutes in each session.

Study groups in NCT06978972
Study groupRoleWhat they receive
Cognitive stimulation therapy groupExperimentalThe CST group will participate in a screening measure where they will perform the Alzheimer's Disease Assessment Scale Cognitive Subscale (ADAS-Cog) to assess for cognitive impairment. The participants will then participate in the Montreal Cognitive Assessment (MoCA) and the Observational Measurement of Engagement (OME) prior to and after the 7-week CST program. The group will receive CST, which is an evidence-based, cognitively stimulating therapeutic group intervention, two times per week for 7 weeks for 45 minutes. The general structure of each session will follow the CST Manual called "Making a Difference 1" and each participant will participate in an introduction, theme song, current affairs activity, the main activity (theme-based activities), and closure each session.
Receives: Other: Cognitive Stimulation Therapy

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Montreal Cognitive Assessment (MoCA)

    The MoCA assesses multiple areas of cognition such as attention, orientation, delayed recall, working memory, executive functioning, visuospatial, and language. The MoCA will take approximately 10 minutes to administer. MoCA scores range from 0 to 30, with higher scores indicating better cognitive functioning. Scores between 10 and 25 typically reflect mild to moderate cognitive impairment, and a score within this range is required for study inclusion. Therefore, only participants scoring between 10 and 25 at baseline will be enrolled, and we will assess whether their cognitive functioning improves from this initial range over the seven weeks.

    Measured: From/after the completion of enrollment (middle to end of June 2025) to after the completion of the 7-week CST sessions (week of August 18th).

  2. The Observational Measurement of Engagement - OME Modified

    The OME is a measurement tool used for individuals with dementia to document direct observations regarding their level of engagement during an activity. The OME assesses an individual's response to the stimuli during an activity by taking note of their attention and attitude using a rating scale. The OME also assesses the individual's cognitive and fine motor difficulty during the task, as well as, the duration and frequency of interactions in the task to determine overall engagement. The OME will take between 3 and 15 minutes to administer. Three minutes if the participant is disengaged with the stimulus and 15 minutes if the participant is engaged the entire time. The OME Modified scoring system includes variable ranges depending on the domain assessed. For attitude and attention, scores range from 1 to 7, with higher scores indicating better outcomes. For activity, scores range from 0 to 3, where a score of 3 represents a greater time the participant was manifesting the activites.

    Measured: From/after the completion of enrollment (middle to end of June 2025) to after the completion of the 7-week CST sessions (week of August 18th).

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted18 May 2025
  2. Study start14 May 2025
  3. Primary completion20 Aug 2025
  4. Study completion20 Aug 2025

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
10 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06978972
Sponsor's protocol ID
IRB#: 2562
Status last verified
Sep 2025
First submitted
2 May 2025
Last updated
25 Sep 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: We will share de-identified IPD that underlies the results reported in the primary publication. This includes individual-level data on demographics, baseline characteristics, outcome measures, and adverse events. Personally identifiable information will be removed to protect participant privacy.

Questions about this trial

What is this clinical trial studying?

A study testing Cognitive Stimulation Therapy in people with Dementia in Nursing Home, run by Northern Kentucky University at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 25 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Montreal Cognitive Assessment (MoCA) (time frame: From/after the completion of enrollment (middle to end of June 2025) to after the completion of the 7-week CST sessions (week of August 18th).). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Sep 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in